Template:Growth factor receptor modulators - Revision history

Prab: 1 revision imported

2025-03-08T19:03:22Z

1 revision imported

← Older revision	Revision as of 19:03, 8 March 2025
(No difference)

Prab: CSV import

2024-04-30T08:15:57Z

CSV import

← Older revision		Revision as of 08:15, 30 April 2024
Line 5:		Line 5:
	\| bodyclass = hlist		\| bodyclass = hlist
	\| groupstyle = text-align:center;		\| groupstyle = text-align:center;
	\| border = {{{border\|}}}<!-- for embedding in other navbox templates -->		\| border = {{{border\|}}}<!--for embedding in other navbox templates-->

	\| group1 = [[Angiopoietin receptor\|Angiopoietin]]		\| group1 = [[Angiopoietin receptor\|Angiopoietin]]
Line 32:		Line 32:
	\| groupstyle = text-align:center;		\| groupstyle = text-align:center;

	<!-- Breakdown of ErbBRs and ligands: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3570895/table/T1/ -->		<!--Breakdown of ErbBRs and ligands: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3570895/table/T1/-->

	\| group1 = [[Epidermal growth factor receptor\|EGF<br /><small>(ErbB1/HER1)</small>]]		\| group1 = [[Epidermal growth factor receptor\|EGF<br /><small>(ErbB1/HER1)</small>]]
Line 47:		Line 47:

	* ''Kinase inhibitors:'' [[Afatinib]]		* ''Kinase inhibitors:'' [[Afatinib]]
			* [[AG-490]]
	* [[Agerafenib]]		* [[Agerafenib]]
	* [[Brigatinib]]		* [[Brigatinib]]
Line 79:		Line 80:
	* [[Pertuzumab]]		* [[Pertuzumab]]
	* [[Trastuzumab]]		* [[Trastuzumab]]
	* [[Trastuzumab deruxtecan]]
	* [[Trastuzumab duocarmazine]]		* [[Trastuzumab duocarmazine]]
	* [[Trastuzumab emtansine]]		* [[Trastuzumab emtansine]]

	* ''Kinase inhibitors:'' [[Afatinib]]		* ''Kinase inhibitors:'' [[Afatinib]]
			* [[AG-490]]
	* [[Lapatinib]]		* [[Lapatinib]]
	* [[Mubritinib]]		* [[Mubritinib]]
Line 110:		Line 111:
	\| groupstyle = text-align:center;		\| groupstyle = text-align:center;

	<!-- Breakdown of FGFRs and ligands: https://books.google.com/books?id=CNwLlih2C60C&lpg=PA216&pg=PA216 -->		<!--Breakdown of FGFRs and ligands: https://books.google.com/books?id=CNwLlih2C60C&lpg=PA216&pg=PA216-->

	\| group1 = [[Fibroblast growth factor receptor 1\|FGFR1]]		\| group1 = [[Fibroblast growth factor receptor 1\|FGFR1]]
Line 133:		Line 134:
	* ''Antibodies:'' [[Aprutumab]]		* ''Antibodies:'' [[Aprutumab]]
	* [[Aprutumab ixadotin]]		* [[Aprutumab ixadotin]]

	* ''Kinase inhibitors:'' [[Infigratinib]]

	\| group3 = [[Fibroblast growth factor receptor 3\|FGFR3]]		\| group3 = [[Fibroblast growth factor receptor 3\|FGFR3]]
Line 166:		Line 165:
	\| group5 = [[Hepatocyte growth factor receptor\|HGF (c-Met)]]		\| group5 = [[Hepatocyte growth factor receptor\|HGF (c-Met)]]
	\| list5 =		\| list5 =
	* ''Agonists'': ~~[[Fosgonimeton]]~~		* ''Agonists'': [[Hepatocyte growth factor]]
	* [[Hepatocyte growth factor]]

	* ''Potentiators:'' [[Dihexa\|Dihexa (PNB-0408)]]		* ''Potentiators:'' [[Dihexa\|Dihexa (PNB-0408)]]
Line 282:		Line 280:

	* ''Kinase inhibitors:'' [[Agerafenib]]		* ''Kinase inhibitors:'' [[Agerafenib]]
	* [[Avapritinib]]
	* [[Axitinib]]		* [[Axitinib]]
	* [[Crenolanib]]		* [[Crenolanib]]
Line 420:		Line 417:
	* [[7,8,2'-Trihydroxyflavone\|7,8,2'-THF]]		* [[7,8,2'-Trihydroxyflavone\|7,8,2'-THF]]
	* [[7,8,3'-Trihydroxyflavone\|7,8,3'-THF]]		* [[7,8,3'-Trihydroxyflavone\|7,8,3'-THF]]
	* [[Amitriptyline]]<!-- Weak and highly non-selective -->		* [[Amitriptyline]]<!--Weak and highly non-selective-->
	* [[Brain-derived neurotrophic factor\|BDNF]]		* [[Brain-derived neurotrophic factor\|BDNF]]
	* [[BNN-20]]		* [[BNN-20]]
	* [[Deoxygedunin]]		* [[Deoxygedunin]]
	* [[Deprenyl]]		* [[Deprenyl]]
	* [[Diosmetin]]<!-- Weak -->		* [[Diosmetin]]<!--Weak-->
	* [[DMAQ-B1]]		* [[DMAQ-B1]]
	* [[HIOC]]		* [[HIOC]]
Line 479:		Line 476:
	}}		}}

	\| group13 = [[Vascular endothelial growth factor receptor\|VEGF]]<!-- two receptors: VEGFR1 (FLT1R), VEGFR2 (KDR) -->		\| group13 = [[Vascular endothelial growth factor receptor\|VEGF]]<!--two receptors: VEGFR1 (FLT1R), VEGFR2 (KDR)-->
	\| list13 =		\| list13 =
	* ''Agonists:'' [[Placental growth factor\|Placental growth factor (PGF)]]		* ''Agonists:'' [[Placental growth factor\|Placental growth factor (PGF)]]
Line 493:		Line 490:
	* [[Cabozantinib]]		* [[Cabozantinib]]
	* [[Cediranib]]		* [[Cediranib]]
	* [[Fruquintinib]]
	* [[Lapatinib]]		* [[Lapatinib]]
	* [[Lenvatinib]]		* [[Lenvatinib]]
Line 541:		Line 537:

	* ''Additional growth factor receptor modulators:'' [[Cerebrolysin]] (neurotrophin mixture)		* ''Additional growth factor receptor modulators:'' [[Cerebrolysin]] (neurotrophin mixture)

			\| below =
			;See also
			: ''[[Template:Receptor modulators\|Receptor/signaling modulators]]''
			: ''[[Template:Signaling peptide/protein receptor modulators\|Signaling peptide/protein receptor modulators]]''
			: ''[[Template:Cytokine receptor modulators\|Cytokine receptor modulators]]''

	}}<noinclude>		}}<noinclude>
Line 546:		Line 548:
	[[Category:Drug templates by receptor, channel, or pump]]		[[Category:Drug templates by receptor, channel, or pump]]
	</noinclude>		</noinclude>
			{{no-index-template}}

en>Whywhenwhohow: add fruquintinib

2023-11-10T02:04:36Z

add fruquintinib

New page

{{Navbox
| name = Growth factor receptor modulators
| title = [[Growth factor receptor]] [[receptor modulator|modulator]]s
| state = {{{state<includeonly>|collapsed</includeonly>}}}
| bodyclass = hlist
| groupstyle = text-align:center;
| border = {{{border|}}}

| group1 = [[Angiopoietin receptor|Angiopoietin]]
| list1 =
* ''Agonists:'' [[Angiopoietin 1]]
* [[Angiopoietin 4]]

* ''Antagonists:'' [[Angiopoietin 2]]
* [[Angiopoietin 3]]

* ''Kinase inhibitors:'' [[Altiratinib]]
* [[CE-245677]]
* [[Rebastinib]]

* ''Antibodies:'' [[Evinacumab]] (against angiopoietin 3)
* [[Nesvacumab]] (against angiopoietin 2)

| group2 = [[Ciliary neurotrophic factor receptor|CNTF]]
| list2 =
* ''Agonists:'' [[Axokine]]
* [[Ciliary neurotrophic factor receptor|CNTF]]
* [[Dapiclermin]]

| group3 = [[Epidermal growth factor receptor|EGF (ErbB)]]
| list3 = {{Navbox|subgroup
| groupstyle = text-align:center;



| group1 = [[Epidermal growth factor receptor|EGF (ErbB1/HER1)]]
| list1 =
* ''Agonists'': [[Amphiregulin]]
* [[Betacellulin]]
* [[Epidermal growth factor|EGF (urogastrone)]]
* [[Epigen]]
* [[Epiregulin]]
* [[Heparin-binding EGF-like growth factor|Heparin-binding EGF-like growth factor (HB-EGF)]]
* [[Murodermin]]
* [[Nepidermin]]
* [[Transforming growth factor alpha|Transforming growth factor alpha (TGFα)]]

* ''Kinase inhibitors:'' [[Afatinib]]
* [[Agerafenib]]
* [[Brigatinib]]
* [[Canertinib]]
* [[Dacomitinib]]
* [[Erlotinib]]
* [[Gefitinib]]
* [[Grandinin]]
* [[Icotinib]]
* [[Lapatinib]]
* [[Neratinib]]
* [[Osimertinib]]
* [[Vandetanib]]
* [[WHI-P 154]]

* ''Antibodies:'' [[Cetuximab]]
* [[Depatuxizumab]]
* [[Depatuxizumab mafodotin]]
* [[Futuximab]]
* [[Imgatuzumab]]
* [[Matuzumab]]
* [[Necitumumab]]
* [[Nimotuzumab]]
* [[Panitumumab]]
* [[Zalutumumab]]

| group2 = [[HER2/neu|ErbB2/HER2]]
| list2 =
* ''Agonists'': ''Unknown/none''

* ''Antibodies:'' [[Ertumaxomab]]
* [[Pertuzumab]]
* [[Trastuzumab]]
* [[Trastuzumab deruxtecan]]
* [[Trastuzumab duocarmazine]]
* [[Trastuzumab emtansine]]

* ''Kinase inhibitors:'' [[Afatinib]]
* [[Lapatinib]]
* [[Mubritinib]]
* [[Neratinib]]
* [[Tucatinib]]

| group3 = [[HER3|ErbB3/HER3]]
| list3 =
* ''Agonists:'' [[Neuregulin|Neuregulins (heregulins)]] ([[Neuregulin-1|1]], [[NRG2|2]], [[CSPG5|6 (neuroglycan C)]])

* ''Antibodies:'' [[Duligotumab]]
* [[Patritumab]]
* [[Seribantumab]]

| group4 = [[HER4|ErbB4/HER4]]
| list4 =
* ''Agonists:'' [[Betacellulin]]
* [[Epigen]]
* [[Heparin-binding EGF-like growth factor|Heparin-binding EGF-like growth factor (HB-EGF)]]
* [[Neuregulin|Neuregulins (heregulins)]] ([[Neuregulin-1|1]], [[NRG2|2]], [[NRG3|3]], [[NRG4|4]], [[Tomoregulin|5 (tomoregulin, TMEFF)]])

}}

| group4 = [[Fibroblast growth factor receptor|FGF]]
| list4 = {{Navbox|subgroup
| groupstyle = text-align:center;



| group1 = [[Fibroblast growth factor receptor 1|FGFR1]]
| list1 =
* ''Agonists:'' [[Ersofermin]]
* [[Fibroblast growth factor|FGF]] ([[FGF1|1]], [[FGF2|2 (bFGF)]], [[FGF3|3]], [[FGF4|4]], [[FGF5|5]], [[FGF6|6]], [[FGF8|8]], [[FGF10|10 (KGF2)]], [[FGF20|20]])
* [[Repifermin]]
* [[Selpercatinib]]
* [[Trafermin]]
* [[Velafermin]]

| group2 = [[Fibroblast growth factor receptor 2|FGFR2]]
| list2 =
* ''Agonists:'' [[Ersofermin]]
* [[Fibroblast growth factor|FGF]] ([[FGF1|1]], [[FGF2|2 (bFGF)]], [[FGF3|3]], [[FGF4|4]], [[FGF5|5]], [[FGF6|6]], [[FGF7|7]] ([[keratinocyte growth factor|KGF]]), [[FGF8|8]], [[FGF9|9]], [[FGF10|10 (KGF2)]], [[FGF17|17]], [[FGF18|18]], [[FGF22|22]])
* [[Palifermin]]
* [[Repifermin]]
* [[Selpercatinib]]
* [[Sprifermin]]
* [[Trafermin]]

* ''Antibodies:'' [[Aprutumab]]
* [[Aprutumab ixadotin]]

* ''Kinase inhibitors:'' [[Infigratinib]]

| group3 = [[Fibroblast growth factor receptor 3|FGFR3]]
| list3 =
* ''Agonists:'' [[Ersofermin]]
* [[Fibroblast growth factor|FGF]] ([[FGF1|1]], [[FGF2|2 (bFGF)]], [[FGF4|4]], [[FGF8|8]], [[FGF9|9]], [[FGF18|18]], [[FGF23|23]])
* [[Selpercatinib]]
* [[Sprifermin]]
* [[Trafermin]]

* ''Antibodies:'' [[Burosumab]] (against FGF23)

| group4 = [[Fibroblast growth factor receptor 4|FGFR4]]
| list4 =
* ''Agonists:'' [[Ersofermin]]
* [[Fibroblast growth factor|FGF]] ([[FGF1|1]], [[FGF2|2 (bFGF)]], [[FGF4|4]], [[FGF6|6]], [[FGF8|8]], [[FGF9|9]], [[FGF19|19]])
* [[Trafermin]]

| group5 = [[Fibroblast growth factor receptor-like 1|FGFRL1 (FGFR5)]]
| list5 =

| group6 = [[Fibroblast growth factor receptor-like 1|PERB1 (FGFR6)]]
| list6 =

| group7 = Unsorted
| list7 =
* ''Agonists:'' [[FGF15/19]]

}}

| group5 = [[Hepatocyte growth factor receptor|HGF (c-Met)]]
| list5 =
* ''Agonists'': [[Fosgonimeton]]
* [[Hepatocyte growth factor]]

* ''Potentiators:'' [[Dihexa|Dihexa (PNB-0408)]]

* ''Kinase inhibitors:'' [[Altiratinib]]
* [[AM7 (drug)|AM7]]
* [[AMG-458]]
* [[Amuvatinib]]
* [[BMS-777607]]
* [[Cabozantinib]]
* [[Capmatinib]]
* [[Crizotinib]]
* [[Foretinib]]
* [[Golvatinib]]
* [[INCB28060]]
* [[JNJ-38877605]]
* [[K252a]]
* [[MK-2461]]
* [[PF-04217903]]
* [[PF-2341066]]
* [[PHA-665752]]
* [[SU-11274]]
* [[Tivantinib]]
* [[Volitinib]]

* ''Antibodies:'' [[Emibetuzumab]]
* [[Ficlatuzumab]]
* [[Flanvotumab]]
* [[Onartuzumab]]
* [[Rilotumumab]]
* [[Telisotuzumab]]
* [[Telisotuzumab vedotin]]

| group6 = [[Somatomedin receptor|IGF]]
| list6 = {{Navbox|subgroup
| groupstyle = text-align:center;

| group1 = [[Insulin-like growth factor 1 receptor|IGF-1]]
| list1 =
* ''Agonists'': [[des(1-3)IGF-1]]
* [[Insulin-like growth factor 1|Insulin-like growth factor-1 (somatomedin C)]]
* [[IGF-1 LR3]]
* [[Insulin-like growth factor 2|Insulin-like growth factor-2 (somatomedin A)]]
* [[Insulin]]
* [[Mecasermin]]
* [[Mecasermin rinfabate]]

* ''Kinase inhibitors:'' [[BMS-754807]]
* [[Linsitinib]]
* [[NVP-ADW742]]
* [[NVP-AEW541]]
* [[OSl-906]]

* ''Antibodies:'' [[AVE-1642]]
* [[Cixutumumab]]
* [[Dalotuzumab]]
* [[Figitumumab]]
* [[Ganitumab]]
* [[Robatumumab]]
* [[R1507]]
* [[Teprotumumab]]
* [[Xentuzumab]] (against IGF-1 and IGF-2)

| group2 = [[Insulin-like growth factor 2 receptor|IGF-2]]
| list2 =
* ''Agonists'': [[Insulin-like growth factor 2|Insulin-like growth factor-2 (somatomedin A)]]

* ''Antibodies:'' [[Dusigitumab]]
* [[Xentuzumab]] (against IGF-1 and IGF-2)

| group3 = Others
| list3 =
* ''Binding proteins:'' [[Insulin-like growth factor-binding protein|IGFBP]] ([[IGFBP1|1]], [[IGFBP2|2]], [[IGFBP3|3]], [[IGFBP4|4]], [[IGFBP5|5]], [[IGFBP6|6]], [[IGFBP7|7]])

* ''Cleavage products/derivatives with unknown target:'' [[Glypromate|Glypromate (GPE, (1-3)IGF-1)]]
* [[Trofinetide]]

}}

| group7 = [[Low-affinity nerve growth factor receptor|LNGF (p75NTR)]]
| list7 =
* ''Agonists:'' [[Brain-derived neurotrophic factor|BDNF]]
* [[BNN-20]]
* [[BNN-27]]
* [[Cenegermin]]
* [[Dehydroepiandrosterone|DHEA]]
* [[Dehydroepiandrosterone sulfate|DHEA-S]]
* [[Nerve growth factor|NGF]]
* [[Neurotrophin-3|NT-3]]
* [[Neurotrophin-4|NT-4]]

* ''Antagonists:'' [[ALE-0540]]
* [[Dexamethasone]]
* [[EVT-901|EVT-901 (SAR-127963)]]
* [[Testosterone]]

* ''Antibodies:'' ''Against NGF:'' [[ABT-110|ABT-110 (PG110)]]
* [[ASP-6294]]
* [[Fasinumab]]
* [[Frunevetmab]]
* [[Fulranumab]]
* [[MEDI-578]]
* [[Ranevetmab]]
* [[Tanezumab]]

* ''Aptamers:'' ''Against NGF:'' [[RBM-004]]

* ''Decoy receptors:'' [[LEVI-04|LEVI-04 (p75NTR-Fc)]]

| group8 = [[Platelet-derived growth factor receptor|PDGF]]
| list8 =
* ''Agonists:'' [[Becaplermin]]
* [[Platelet-derived growth factor|Platelet-derived growth factor]] ([[PDGFA|A]], [[PDGFB|B]], [[PDGFC|C]], [[PDGFD|D]])

* ''Kinase inhibitors:'' [[Agerafenib]]
* [[Avapritinib]]
* [[Axitinib]]
* [[Crenolanib]]
* [[Imatinib]]
* [[Lenvatinib]]
* [[Masitinib]]
* [[Motesanib]]
* [[Nintedanib]]
* [[Pazopanib]]
* [[Radotinib]]
* [[Quizartinib]]
* [[Ripretinib]]
* [[Sunitinib]]
* [[Sorafenib]]
* [[Toceranib]]

* ''Antibodies:'' [[Olaratumab]]
* [[Ramucirumab]]
* [[Tovetumab]]

| group9 = [[RET proto-oncogene|RET (GFL)]]
| list9 = {{Navbox|subgroup
| groupstyle = text-align:center;

| group1 = [[GFRα1]]
| list1 =
* ''Agonists:'' [[Glial cell line-derived neurotrophic factor|Glial cell line-derived neurotrophic factor (GDNF)]]
* [[Liatermin]]

* ''Kinase inhibitors:'' [[Vandetanib]]

| group2 = [[GFRα2]]
| list2 =
* ''Agonists:'' [[Neurturin|Neurturin (NRTN)]]

* ''Kinase inhibitors:'' [[Vandetanib]]

| group3 = [[GFRα3]]
| list3 =
* ''Agonists:'' [[Artemin|Artemin (ARTN)]]

* ''Kinase inhibitors:'' [[Vandetanib]]

| group4 = [[GFRα4]]
| list4 =
* ''Agonists:'' [[Persephin|Persephin (PSPN)]]

* ''Kinase inhibitors:'' [[Vandetanib]]

| group5 = Unsorted
| list5 =
* ''Kinase inhibitors:'' [[Agerafenib]]

}}

| group10 = [[CD117|SCF (c-Kit)]]
| list10 =
* ''Agonists:'' [[Ancestim]]
* [[Stem cell factor]]

* ''Kinase inhibitors:'' [[Agerafenib]]
* [[Axitinib]]
* [[Dasatinib]]
* [[Imatinib]]
* [[Masitinib]]
* [[Nilotinib]]
* [[Pazopanib]]
* [[Quizartinib]]
* [[Sorafenib]]
* [[Sunitinib]]
* [[Toceranib]]

| group11 = [[Transforming growth factor beta receptor|TGFβ]]
| list11 =
* See [[Template:TGFβ_receptor_superfamily_modulators|here]] instead.

| group12 = [[Trk receptor|Trk]]
| list12 = {{Navbox|subgroup
| groupstyle = text-align:center;

| group1 = [[TrkA receptor|TrkA]]
| list1 =
* ''Agonists:'' [[Amitriptyline]]
* [[BNN-20]]
* [[BNN-27]]
* [[Cenegermin]]
* [[Dehydroepiandrosterone|DHEA]]
* [[Dehydroepiandrosterone sulfate|DHEA-S]]
* [[Gambogic amide]]
* [[Nerve growth factor|NGF]]
* [[Tavilermide]]

* ''Antagonists:'' [[ALE-0540]]
* [[Dexamethasone]]
* [[FX007]]
* [[Testosterone]]

* ''Negative allosteric modulators:'' [[VM-902A]]

* ''Kinase inhibitors:'' [[Altiratinib]]
* [[AZD-6918]]
* [[CE-245677]]
* [[CH-7057288]]
* [[DS-6051]]
* [[Entrectinib]]
* [[GZ-389988]]
* [[K252a]]
* [[Larotrectinib]]
* [[Lestaurtinib]]
* [[Milciclib]]
* [[ONO-4474]]
* [[ONO-5390556]]
* [[PLX-7486]]
* [[Rebastinib]]
* [[SNA-120|SNA-120 (pegylated K252a)]])

* ''Antibodies:'' ''Against TrkA:'' [[GBR-900]]; ''Against NGF:'' [[ABT-110|ABT-110 (PG110)]]
* [[ASP-6294]]
* [[Fasinumab]]
* [[Frunevetmab]]
* [[Fulranumab]]
* [[MEDI-578]]
* [[Ranevetmab]]
* [[Tanezumab]]

* ''Aptamers:'' ''Against NGF:'' [[RBM-004]]

* ''Decoy receptors:'' [[ReN-1820|ReN-1820 (TrkAd5)]]

| group2 = [[TrkB receptor|TrkB]]
| list2 =
* ''Agonists:'' [[3,7-Dihydroxyflavone|3,7-DHF]]
* [[3,7,8,2'-Tetrahydroxyflavone|3,7,8,2'-THF]]
* [[4'-Dimethylamino-7,8-dihydroxyflavone|4'-DMA-7,8-DHF]]
* [[7,3′-Dihydroxyflavone|7,3'-DHF]]
* [[7,8-Dihydroxyflavone|7,8-DHF]]
* [[7,8,2'-Trihydroxyflavone|7,8,2'-THF]]
* [[7,8,3'-Trihydroxyflavone|7,8,3'-THF]]
* [[Amitriptyline]]
* [[Brain-derived neurotrophic factor|BDNF]]
* [[BNN-20]]
* [[Deoxygedunin]]
* [[Deprenyl]]
* [[Diosmetin]]
* [[DMAQ-B1]]
* [[HIOC]]
* [[LM22A-4]]
* [[N-Acetylserotonin]]
* [[Neurotrophin-3|NT-3]]
* [[Neurotrophin-4|NT-4]]
* [[Norwogonin|Norwogonin (5,7,8-THF)]]
* [[R7 (drug)|R7]]
* [[R13 (drug)|R13]]
* [[TDP6]]

* ''Antagonists:'' [[ANA-12]]
* [[Cyclotraxin B]]
* [[Gossypetin|Gossypetin (3,5,7,8,3',4'-HHF)]]

* ''Ligands:'' [[Dehydroepiandrosterone|DHEA]]

* ''Kinase inhibitors:'' [[Altiratinib]]
* [[AZD-6918]]
* [[CE-245677]]
* [[CH-7057288]]
* [[DS-6051]]
* [[Entrectinib]]
* [[GZ-389988]]
* [[K252a]]
* [[Larotrectinib]]
* [[Lestaurtinib]]
* [[ONO-4474]]
* [[ONO-5390556]]
* [[PLX-7486]]

| group3 = [[TrkC receptor|TrkC]]
| list3 =
* ''Agonists:'' [[BNN-20]]
* [[Dehydroepiandrosterone|DHEA]]
* [[Neurotrophin-3|NT-3]]

* ''Kinase inhibitors:'' [[Altiratinib]]
* [[AZD-6918]]
* [[CE-245677]]
* [[CH-7057288]]
* [[DS-6051]]
* [[Entrectinib]]
* [[GZ-389988]]
* [[K252a]]
* [[Larotrectinib]]
* [[Lestaurtinib]]
* [[ONO-4474]]
* [[ONO-5390556]]
* [[PLX-7486]]

}}

| group13 = [[Vascular endothelial growth factor receptor|VEGF]]
| list13 =
* ''Agonists:'' [[Placental growth factor|Placental growth factor (PGF)]]
* [[Ripretinib]]
* [[Telbermin]]
* [[Vascular endothelial growth factor|VEGF]] ([[Vascular endothelial growth factor A|A]], [[Vascular endothelial growth factor B|B]], [[Vascular endothelial growth factor C|C]], [[Vascular endothelial growth factor D|D (FIGF)]])

* ''Allosteric modulators:'' [[Cyclotraxin B]]

* ''Kinase inhibitors:'' [[Agerafenib]]
* [[Altiratinib]]
* [[Axitinib]]
* [[Cabozantinib]]
* [[Cediranib]]
* [[Fruquintinib]]
* [[Lapatinib]]
* [[Lenvatinib]]
* [[Motesanib]]
* [[Nintedanib]]
* [[Pazopanib]]
* [[Pegaptanib]]
* [[Rebastinib]]
* [[Regorafenib]]
* [[Semaxanib]]
* [[Sorafenib]]
* [[Sunitinib]]
* [[Toceranib]]
* [[Tivozanib]]
* [[Vandetanib]]
* [[WHI-P 154]]

* ''Antibodies:'' [[Alacizumab pegol]]
* [[Bevacizumab]]
* [[Icrucumab]]
* [[Ramucirumab]]
* [[Ranibizumab]]

* ''Decoy receptors:'' [[Aflibercept]]

| group14 = Others
| list14 =
* ''Additional growth factors:'' [[Adrenomedullin]]
* [[Colony-stimulating factor]]s (see [[Template:Cytokine receptor modulators|here]] instead)
* [[Connective tissue growth factor|Connective tissue growth factor (CTGF)]]
* [[Ephrin]]s ([[EFNA1|A1]], [[EFNA2|A2]], [[EFNA3|A3]], [[EFNA4|A4]], [[EFNA5|A5]], [[EFNB1|B1]], [[EFNB2|B2]], [[EFNB3|B3]])
* [[Erythropoietin]] (see [[Template:Cytokine receptor modulators|here]] instead)
* [[Glucose-6-phosphate isomerase|Glucose-6-phosphate isomerase (GPI; PGI, PHI, AMF)]]
* [[Glia maturation factor|Glia maturation factor (GMF)]]
* [[Hepatoma-derived growth factor|Hepatoma-derived growth factor (HDGF)]]
* [[Interleukin]]s/[[T-cell growth factor]]s (see [[Template:Cytokine receptor modulators|here]] instead)
* [[Leukemia inhibitory factor|Leukemia inhibitory factor (LIF)]]
* [[Macrophage-stimulating protein|Macrophage-stimulating protein (MSP; HLP, HGFLP)]]
* [[Midkine|Midkine (NEGF2)]]
* [[Migration-stimulating factor|Migration-stimulating factor (MSF; PRG4)]]
* [[Oncomodulin]]
* [[Pituitary adenylate cyclase-activating peptide|Pituitary adenylate cyclase-activating peptide (PACAP)]]
* [[Pleiotrophin]]
* [[Renalase]]
* [[Thrombopoietin]] (see [[Template:Cytokine receptor modulators|here]] instead)
* [[Wnt signaling pathway|Wnt signaling protein]]s

* ''Additional growth factor receptor modulators:'' [[Cerebrolysin]] (neurotrophin mixture)

}}<noinclude>
{{collapsible option}}
[[Category:Drug templates by receptor, channel, or pump]]
</noinclude>